Shots:

• The P-III RELAY study involves assessing the combination of Cyramza + Erlotinib vs PBO + Erlotinib as a 1L treatment in 499 previously untreated patients with mNSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations across North America- Europe and Asia
• The P-III RELAY study results: improvement in mPFS by 7mos. (19.4 mos. vs 12.4mos.); improvement in 2EPs i.e- DoR- PFS2 and time on targeted therapy; no new safety signals is observed
•  Cyramza is an antiangiogenic therapy targeting VEGFR-2- blocking its binding with ligands (VEGF-A- VEGF-C- and VEGF-D)- thus slowing growth of tumors and has received 5 FDA’s approval to treat 4 different cancer indications

Click here to­ read full press release/ article

 Ref: Eli Lilly | Image: Eli Lilly